ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The company's products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis.

Merck was founded in 1668 as a pharmacy and is the oldest pharmaceutical business in the world. The Merck family owns about 70% of the company. Merck is leaving its mark on the global pharmaceutical market. Through a network of nearly 200 companies in over 60 countries, the Merck develops, makes, and sells pharmaceutical and chemical products for global consumption. Name-brand prescription drugs include treatments for cardiovascular disease, cancers, infertility, and neurological disorders; the company also makes over-the-counter pharmaceuticals. Aside from drugs, the firm makes specialty chemicals, including laboratory reagents and cosmetic ingredients, as well as liquid crystals for televisions.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline. In January 2010, the Company completed the acquisition of Symphony Dynamo, Inc. (SDI) from Symphony Dynamo Holdings LLC. Pursuant to the acquisition SDI became a wholly owned subsidiary of the Company.

Imperial Ginseng Products company cultivates more than 550 acres of North American ginseng root used in traditional Chinese medicine. The company operates a farm in Ontario, Canada, where the root is grown for three or four years (each year increases yield and value), harvested, and dried. Imperial Ginseng Products sells the dried root to buyers in North America and Asia, who then turn it into prepared remedies. CDS & Co owns 55% of the company, while co-chairmen Hugh Cartwright and Stephen McCoach and director Maurice Levesque together hold nearly 40%.

Dainippon Sumitomo Pharma (DSP) is Osaka's answer to disease. The Japanese drugmaker produces drugs in a wide range of therapeutic categories including cardiovascular disease, gastrointestinal disorders, and infections. Its products include blood pressure medication Amlodin, digestive tract treatment Gasmotin, and antibiotic Meropen. Subsidiary Sepracordevelops and markets central nervous system and respiratory drugs in North America; its top selling product is insomnia therapy Lunesta. In addition to pharmaceuticals, DSP makes food and feed additives, veterinary drugs, fine chemicals, and diagnostic reagents used in research and clinical laboratories. Sumitomo Chemical owns just over half of DSP.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, rheumatology, anesthesia, and antidotes in the United States. The company's Ophthalmic Segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, eyelid cleansers, vitamin supplements, and contact lens accessories. The company's Hospital Drugs and Injectables Segment markets specialty injectable pharmaceutical products, including antidotes and anesthesia, as well as products used in the treatment of rheumatoid arthritis and pain management. It markets products to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The company's Biologics and Vaccines Segment markets adult Tetanus-Diphtheria vaccines directly to hospitals and physicians, as well as through wholesalers and national distributors. Its Contract Services Segment manufactures products for third party pharmaceutical and biotechnology customers. The company also markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies.

PML Microbiologicals, Inc. company was founded in 1969 and is headquartered in Wilsonville, Oregon. It has manufacturing facilities in Mississauga, Canada; and Portland, Oregon. As of December 8, 2008, PML Microbiologicals, Inc. operates as a subsidiary of BioMérieux S.A. PML Microbiologicals, Inc. manufactures culture media and microbiological products for clinical and industrial applications in North America. It offers prepared culture media, stains, reagents, quality control organisms, sterility products, and collection and transport systems, as well as accessories for microbiology laboratories. The company also provides custom products, such as minimum inhibitory concentration panels, parasitology kits, diluents, and rinsing fluids. It serves clinical, pharmaceutical, research, environmental, personal care, and food and beverage industries. PML Microbiologicals, Inc. was formerly known as Prepared Media Laboratory.

Provectus Pharmaceuticals, Inc. company was founded in 2002 and is based in Knoxville, Tennessee. Provectus Pharmaceuticals, Inc., a development stage company, specializes in oncology and dermatology therapies. The company is conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for psoriasis and atopic dermatitis. It received orphan drug designation from the FDA for its melanoma indication. In addition to its suite of proprietary drugs, Provectus Pharmaceuticals developed various intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.